Nahla N Younis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9454197/publications.pdf

Version: 2024-02-01

31 papers	737 citations	566801 15 h-index	525886 27 g-index
31 all docs	31 docs citations	31 times ranked	1010 citing authors

#	Article	IF	Citations
1	Alleviation of fructoseâ€induced Alzheimerâ€™s disease in rats by pioglitazone and decaffeinated green coffee bean extract. Journal of Food Biochemistry, 2021, 45, e13715.	1.2	6
2	Inactivation of Wnt/Î²-catenin/renin angiotensin axis by tumor necrosis factor-alpha inhibitor, infliximab, ameliorates CKD induced in rats. Biochemical Pharmacology, 2021, 185, 114426.	2.0	8
3	The efficacy of bone marrow-derived mesenchymal stem cells and/or erythropoietin in ameliorating kidney damage in gamma irradiated rats: Role of non-hematopoietic erythropoietin anti-apoptotic signaling. Life Sciences, 2021, 275, 119388.	2.0	3
4	Potential therapeutic efficacy of pachymic acid in chronic kidney disease induced in rats: role of Wnt/Î²-catenin/reninâ€“angiotensin axis. Journal of Pharmacy and Pharmacology, 2021, , .	1.2	5
5	Resveratrol Ameliorates Aortic Calcification in Ovariectomized Rats via SIRT1 Signaling. Current Issues in Molecular Biology, 2021, 43, 1057-1071.	1.0	12
6	Pachymic Acid Attenuated Doxorubicin-Induced Heart Failure by Suppressing miR-24 and Preserving Cardiac Junctophilin-2 in Rats. International Journal of Molecular Sciences, 2021, 22, 10710.	1.8	14
7	Modulation of brain insulin signaling in Alzheimerâ€™s disease: New insight on the protective role of green coffee bean extract. Nutritional Neuroscience, 2020, 23, 27-36.	1.5	10
8	The modulation of PCSK-9 and GAGs by 10-dehydrogingerdione and pentoxifylline in hyperlipidemic rabbits. Natural Product Research, 2020, 34, 2372-2377.	1.0	3
9	Modulation of NADPH oxidase and Nrf2/HO-1 pathway by vanillin in cisplatin-induced nephrotoxicity in rats. Journal of Pharmacy and Pharmacology, 2020, 72, 1546-1555.	1.2	34
10	Contribution of aorta glycosaminoglycans and PCSK9 to hyperlipidemia in experimental rabbits: the role of 10-dehdrogingerdione as effective modulator. Molecular Biology Reports, 2019, 46, 3921-3928.	1.0	6
11	Silymarin-loaded Eudragit Â® RS100 nanoparticles improved the ability of silymarin to resolve hepatic fibrosis in bile duct ligated rats. Biomedicine and Pharmacotherapy, 2016, 81, 93-103.	2.5	42
12	10-DHGD ameliorates cisplatin-induced nephrotoxicity in rats. Biomedicine and Pharmacotherapy, 2016, 83, 241-246.	2.5	13
13	Silymarin preconditioning protected insulin resistant rats from liver ischemia-reperfusion injury: role of endogenous H2S. Journal of Surgical Research, 2016, 204, 398-409.	0.8	17
14	The synergistic effect between vanillin and doxorubicin in ehrlich ascites carcinoma solid tumor and MCF-7 human breast cancer cell line. Pathology Research and Practice, 2016, 212, 767-777.	1.0	44
15	Bone marrow-derived mesenchymal stem cells effectively regenerate fibrotic liver in bile duct ligation rat model. Experimental Biology and Medicine, 2016, 241, 581-591.	1.1	26
16	Atheroprotective potentials of curcuminoids against ginger extract in hypercholesterolaemic rabbits. Natural Product Research, 2015, 29, 961-965.	1.0	14
17	Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy. Experimental Biology and Medicine, 2013, 238, 881-888.	1.1	17
18	10-Dehydrogingerdione raises HDL-cholesterol through a CETP inhibition and wards off oxidation and inflammation in dyslipidemic rabbits. Atherosclerosis, 2013, 231, 334-340.	0.4	24

#	Article	IF	Citations
19	Small dense LDL is more susceptible to glycation than more buoyant LDL in TypeÂ2 diabetes. Clinical Science, 2013, 124, 343-349.	1.8	46
20	High-density lipoprotein impedes glycation of low-density lipoprotein. Diabetes and Vascular Disease Research, 2013, 10, 152-160.	0.9	27
21	HDL functionality in diabetes mellitus: potential importance of glycation. Clinical Lipidology, 2012, 7, 561-578.	0.4	4
22	Influence of the glucose tolerance test on pro-atherogenic modification of LDL and its relation to paraoxonase activity. Atherosclerosis, 2011, 218, e10.	0.4	0
23	Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients. Annals of Clinical Biochemistry, 2011, 48, 566-571.	0.8	19
24	Gastritis Induced by Helicobacter pylori Infection in Experimental Rats. Digestive Diseases and Sciences, 2010, 55, 2770-2777.	1.1	11
25	Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes. Diabetes and Vascular Disease Research, 2010, 7, 289-295.	0.9	38
26	Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro. Atherosclerosis, 2009, 202, 162-168.	0.4	84
27	GLYCATION OF LDL IS AN IMPORTANT ATHEROGENIC MODIFICATION AND OPPOSED BY PARAOXONASE-RICH HDL. Atherosclerosis, 2009, 207, 306.	0.4	2
28	Variation in paraoxonase-1 activity and atherosclerosis. Current Opinion in Lipidology, 2009, 20, 265-274.	1.2	101
29	Lipoprotein glycation in atherogenesis. Clinical Lipidology, 2009, 4, 781-790.	0.4	12
30	Effect of Some Natural Products Either Alone or in Combination on Gastritis Induced in Experimental Rats. Digestive Diseases and Sciences, 2008, 53, 1774-1784.	1.1	18
31	Glycation as an atherogenic modification of LDL. Current Opinion in Lipidology, 2008, 19, 378-384.	1.2	77